Evan Y. Yu

22.5k total citations · 3 hit papers
294 papers, 5.9k citations indexed

About

Evan Y. Yu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Evan Y. Yu has authored 294 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 179 papers in Pulmonary and Respiratory Medicine, 149 papers in Oncology and 103 papers in Surgery. Recurrent topics in Evan Y. Yu's work include Prostate Cancer Treatment and Research (155 papers), Bladder and Urothelial Cancer Treatments (99 papers) and Cancer Immunotherapy and Biomarkers (73 papers). Evan Y. Yu is often cited by papers focused on Prostate Cancer Treatment and Research (155 papers), Bladder and Urothelial Cancer Treatments (99 papers) and Cancer Immunotherapy and Biomarkers (73 papers). Evan Y. Yu collaborates with scholars based in United States, United Kingdom and France. Evan Y. Yu's co-authors include Michael T. Schweizer, Celestia S. Higano, Heather H. Cheng, Jonathan E. Rosenberg, Daniel P. Petrylak, Bruce Montgomery, Elisabeth I. Heath, Peter S. Nelson, Michael J. Morris and Matthew D. Galsky and has published in prestigious journals such as The Lancet, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Evan Y. Yu

277 papers receiving 5.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study

2010 809 citations Mary‐Ellen Taplin, Evan Y. Yu et al. profile →
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

2019 435 citations Jonathan E. Rosenberg, Elisabeth I. Heath et al. Journal of Clinical Oncology profile →
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial

2021 175 citations Evan Y. Yu, Yohann Loriot et al. profile →

Peers

Countries citing papers authored by Evan Y. Yu

Since Specialization

Citations

This map shows the geographic impact of Evan Y. Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evan Y. Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evan Y. Yu more than expected).

Fields of papers citing papers by Evan Y. Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evan Y. Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evan Y. Yu. The network helps show where Evan Y. Yu may publish in the future.

Co-authorship network of co-authors of Evan Y. Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Evan Y. Yu. A scholar is included among the top collaborators of Evan Y. Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evan Y. Yu. Evan Y. Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer 2025 ·European Urology Oncology ·Niven Mehra, Emmanuel S. Antonarakis, Se Hoon Park, Jeffrey C. Goh, Ray McDermott, (unknown), Peter C.C. Fong, Richard Greil, Maria De Santis, Patricio Yañez, Eric Yi‐Hsiu Huang, Stephen Begbie, Felipe Rey, Gero Kramer, Hiroyoshi Suzuki, (unknown), Sameer R. Ghate, Yi Cui, Christian Hosius, Evan Y. Yu	1
2	Germline and Somatic Genomic Testing for Metastatic Prostate Cancer: ASCO Guideline Clinical Insights 2025 ·JCO Oncology Practice ·(unknown), R. Bryan Rumble, Evan Y. Yu, (unknown)	0
3	1604P PSMA-targeted radioligand therapy (RLT) with 131I-LNTH-1095 (1095) plus enzalutamide (enza) vs enza alone in chemotherapy-naïve patients (pts) whose piflufolastat F 18-avid metastatic castration-resistant prostate cancer (mCRPC) progressed on abiraterone (abi): ARROW 2024 ·Annals of Oncology ·Evan Y. Yu, Vivek Narayan, Giuseppe Esposito, (unknown), Yiping Lu, Mary A. Lilly, Jérémie Calais, (unknown), (unknown), Gary A. Ulaner, Frédéric Pouliot, David Laidley, (unknown), Fred Saad, Yusuf Menda	1
4	A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer. 2024 ·Journal of Clinical Oncology ·Evan Y. Yu, Luke T. Nordquist, Salim Yazji, Yisrael Katz, (unknown), (unknown), Mohamad A. Salkeni, Hamid Emamekhoo, Elisabeth I. Heath, Ivan de Kouchkovsky, Joshua M. Lang, Peter S. Nelson, James B. Breitmeyer, Lawrence Fong, Johann S. de Bono	0
5	Adjuvant Chemotherapy and Survival After Radical Cystectomy in Histologic Subtype Bladder Cancer 2024 ·Clinical Genitourinary Cancer ·(unknown), Dimitra Rafailia Bakaloudi, Fady Ghali, Yaw A. Nyame, George R. Schade, Petros Grivas, Todd Yezefski, Jessica E. Hawley, Evan Y. Yu, Andrew C. Hsieh, Bruce Montgomery, Sarah P. Psutka, John L. Gore, Jonathan L. Wright	3
6	Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to ¹⁷⁷Lu-PSMA-617: A Retrospective Multicenter Cohort Study 2024 ·JCO Precision Oncology ·(unknown), George Mo, (unknown), Laura Graham, Roman Gulati, Colin C. Pritchard, Michael C. Haffner, Todd Yezefski, Jessica E. Hawley, Heather H. Cheng, Evan Y. Yu, Petros Grivas, Bruce Montgomery, Peter S. Nelson, Delphine L. Chen, Thomas A. Hope, Amir Iravani, Michael T. Schweizer	7
7	Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of the cisplatin (cis)-ineligible population from EV-302/KEYNOTE-A39. 2024 ·Journal of Clinical Oncology ·Michiel Simon Van Der Heijden, Shilpa Gupta, Jens Bedke, Begoña P. Valderrama, Eiji Kikuchi, Gopa Iyer, Yohann Loriot, Nancy A. Dawson, Jean Hoffman‐Censits, Nataliya Mar, Srikala S. Sridhar, (unknown), Sang Joon Shin, Evan Y. Yu, Ignacio Durán, (unknown), Xuesong Yu, Aditya Shetty, Abhishek Bavle, Thomas Powles	3
8	CYP11A1 inhibitor MK-5684 versus next-generation hormonal agent (NHA) switch in patients with metastatic castration-resistant prostate cancer (mCRPC) after NHA and taxane-based chemotherapy: Phase 3 MK-5684-003 trial. 2024 ·Journal of Clinical Oncology ·Evan Y. Yu, Yue Song, Christian Poehlein, Charles Schloss, Emmanuel S. Antonarakis	0
9	Hematologic toxicity in ¹⁷⁷lu-PSMA-617 treatment for mCRPC: Unraveling the impact of PSMA PET bone tumor volume (PSMA-bTTV). 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), Roman Gulati, (unknown), Heather H. Cheng, Jessica E. Hawley, Todd Yezefski, Michael C. Haffner, Bruce Montgomery, Peter S. Nelson, Michael T. Schweizer, Evan Y. Yu, Delphine L. Chen, Amir Iravani	3
10	2367P A randomized phase II study of atezolizumab (atezo) plus recombinant human IL-7 (CYT107) vs. atezo alone in patients with locally advanced or metastatic urothelial carcinoma (mUC) 2023 ·Annals of Oncology ·Russell K. Pachynski, Gurkamal Chatta, Rohit Jain, Helen Moon, Randy F. Sweis, (unknown), Fang Tian, Steven P. Fling, André Lacroix, Judith C. Kaiser, Elad Sharon, Evan Y. Yu	1
11	Clinical, pathologic, and molecular features of amphicrine prostate cancer 2023 ·The Prostate ·Laura Graham, Michael C. Haffner, (unknown), (unknown), Michael T. Schweizer, Colin C. Pritchard, Ilsa M. Coleman, Peter S. Nelson, Evan Y. Yu	7
12	418 Phase 1b/2 KEYNOTE-365 cohort I: platinum-containing chemotherapy alone or in combination with pembrolizumab for treatment-emergent neuroendocrine prostate carcinoma 2021 ·SHILAP Revista de lepidopterología ·Johann S. de Bono, Neal D. Shore, Gero Kramer, Anthony M. Joshua, (unknown), Christian Poehlein, Charles Schloss, Evan Y. Yu	2
13	Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance 2021 ·Clinical Cancer Research ·Rana R. McKay, Lucia Kwak, Jett Crowdis, Jamie M. Sperger, Shuang G. Zhao, Wanling Xie, Lillian Werner, Rosina T. Lis, Zhenwei Zhang, Xiao X. Wei, Joshua M. Lang, Eliezer M. Van Allen, Rupal S. Bhatt, Evan Y. Yu, Peter S. Nelson, Glenn J. Bubley, Bruce Montgomery, Mary‐Ellen Taplin	21
14	Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer 2021 ·Clinical Cancer Research ·Elahe A. Mostaghel, Brett T. Marck, Orpheus Kolokythas, Felix S. Chew, Evan Y. Yu, Michael T. Schweizer, Heather H. Cheng, Philip W. Kantoff, Steven P. Balk, Mary‐Ellen Taplin, Nima Sharifi, Alvin M. Matsumoto, Peter S. Nelson, Bruce Montgomery	17
15	Whole-Body [18F]-Fluoride PET SUV Imaging to Monitor Response to Dasatinib Therapy in Castration-Resistant Prostate Cancer Bone Metastases: Secondary Results from ACRIN 6687 2021 ·Tomography ·Mark Muzi, Finbarr O’Sullivan, (unknown), (unknown), David A. Mankoff, (unknown), (unknown), Evan Y. Yu	1
16	Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies 2020 ·PLoS ONE ·Laura Graham, Bruce Montgomery, Heather H. Cheng, Evan Y. Yu, Peter S. Nelson, Colin C. Pritchard, (unknown), Ajjai Alva, Michael T. Schweizer	63
17	Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T 2020 ·JNCI Journal of the National Cancer Institute ·Ravi A. Madan, Emmanuel S. Antonarakis, Charles G. Drake, Lawrence Fong, Evan Y. Yu, Douglas G. McNeel, Daniel W. Lin, Nancy N. Chang, Nadeem A. Sheikh, James L. Gulley	51
18	Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle‐invasive bladder cancer 2019 ·Cancer ·Alberto Martini, Rachel Jia, Bart S. Ferket, Nikhil Waingankar, Elizabeth R. Plimack, Simon J. Crabb, Lauren C. Harshman, Evan Y. Yu, Thomas Powles, Jonathan E. Rosenberg, Sumanta K. Pal, Ulka N. Vaishampayan, Andrea Necchi, Peter Wiklund, Reza Mehrazin, Madhu Mazumdar, John P. Sfakianos, Matthew D. Galsky	26
19	Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial 2016 ·Clinical Cancer Research ·Emmanuel S. Antonarakis, Adam S. Kibel, Evan Y. Yu, Lawrence I. Karsh, Aymen Elfiky, Neal D. Shore, Nicholas J. Vogelzang, John M. Corman, Frederick Millard, Johnathan C. Maher, Nancy N. Chang, Todd DeVries, Nadeem Ahmed Sheikh, Charles G. Drake	60
20	A phase I study of the recombinant human IgG1 anti-IGF-IR monoclonal antibody (Mab) IMC-A12, administered on a weekly basis to patients with advanced solid tumors: Interim analysis 2007 ·Molecular Cancer Therapeutics ·(unknown), Patricia LoRusso, Michael A. Gordon, Evan Y. Yu, Samuel H. Whiting, Floyd E. Fox, Terry Katz, Eric K. Rowinsky, Hagop Youssoufian	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact